Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uric Acid SCHEMBL29364704 | 0.72 | MAPT (0.42) | MAPTADORA3ADORA2AADORA1XDH | |
| SCHEMBL22144 | 0.70 | MAPT (1.00) | MAPTRPS6KA3DYRK1AXDHADORA2B | |
| SCHEMBL1511914 | 0.68 | MAPT (0.52) | MAPTADORA3ADORA2AADORA1RPS6KA3 | |
| SCHEMBL21895408 | 0.67 | MAPT (0.50) | MAPTADORA3ADORA2AADORA1RPS6KA3 | |
| SCHEMBL21895487 | 0.67 | MAPT (0.50) | MAPTADORA3ADORA2AADORA1RPS6KA3 | |
| SCHEMBL14933942 | 0.65 | MAPT (0.48) | MAPTADORA3ADORA2AADORA1RPS6KA3 | |
| SCHEMBL447389 | 0.65 | MAPT (0.84) | MAPTRPS6KA3DYRK1AXDHADORA2B | |
| SCHEMBL15713240 | 0.65 | GDA (0.44) | MAPTLMNAL3MBTL1GDAPNP | |
| SCHEMBL36691 | 0.64 | — | — | |
| SCHEMBL31495235 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230416361-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | claimed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3519558-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | Organovo, Inc. (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064323-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | ORGANOVO, INC. (US) | 2018-04-05 | — | — | WO | claimed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | claimed |
| JP-3065650-A | — | — | None | — | — | JP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4705318-A2 | KIDNEY-TARGETING AAV CAPSIDS AND METHODS OF USE THEREOF | Oregon Health & Science University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | disclosed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| JP-H0365650-A | METHOD OF MEASURING DIHYDROXYADENINE | FUJIREBIO INC | 1991-03-20 | — | — | JP | disclosed |
| JP-H00365650-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | MAPT 4410/4885ADORA3 2810/4885ADORA2A 3060/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | MAPT 1585/4885ADORA3 3619/4885ADORA2A 3124/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | MAPT 3104/4885ADORA3 4579/4885ADORA2A 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.